Itrapelet 100 Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various fungal infections. Itraconazole exerts its antifungal activity by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. Disruption of ergosterol synthesis leads to increased membrane permeability and ultimately fungal cell death. Itrapelet 100 is effective against a wide range of pathogenic fungi including dermatophytes, yeasts such as Candida species, and molds including Aspergillus species. It is commonly prescribed for conditions such as onychomycosis, blastomycosis, histoplasmosis, aspergillosis, and other systemic or superficial mycoses. The capsule formulation ensures optimal bioavailability when taken with food, enhancing absorption. Dosage and duration of therapy should be individualized based on the type and severity of infection, with monitoring for potential adverse effects such as hepatotoxicity, gastrointestinal disturbances, and drug interactions due to its influence on cytochrome P450 enzymes. Itrapelet 100 Capsule should be used under medical supervision, with caution advised in patients with hepatic impairment or congestive heart failure.